<DOC>
	<DOCNO>NCT01015677</DOCNO>
	<brief_summary>This study ass safety , tolerability , efficacy MK-6913 treatment moderate-to-very-severe vasomotor symptom ( hot flash hot flush ) postmenopausal woman . The primary study hypothesis one dose MK-6913 result significantly great reduction baseline , compare placebo , number moderate severe hot flash 4 week treatment .</brief_summary>
	<brief_title>A Study MK-6913 Treatment Hot Flashes Postmenopausal Women ( 6913-004 )</brief_title>
	<detailed_description />
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Woman least 50 moderate severe hot flash episode per week Postmenopausal Between 45 60 year age naturally menopausal , 35 60 underwent bilateral oophorectomy Not receive hormone therapy Has normal mammogram normal Pap test past 6 month Generally healthy A history cancer , except certain skin cancer Undiagnosed vaginal bleeding uterine endometrial disorder Currently use tobacco product , use last 6 month Has human immunodeficiency virus ( HIV )</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>